Novo Nordisk's consensus analyst price target has recently been revised downward from DKK 438.59 to DKK 431.99, marking a modest decrease in sentiment. This adjustment comes amid a modest uptick in ...

Dems accept shutdown deal without ACA guarantee; RFK Jr. wades into menopause treatment fray; Novo shares rise despite loss ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Metsera, the US biotech with a pipeline of next-generation metabolic hormone weight loss drugs, has agreed a sale to Pfizer ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.